• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OCS

    Oculis Holding AG

    Subscribe to $OCS
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Oculis Holding AG

    DatePrice TargetRatingAnalyst
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    4/28/2023$27.00Outperform
    Wedbush
    See more ratings

    Oculis Holding AG Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Oculis Holding AG

      SC 13G - Oculis Holding AG (0001953530) (Subject)

      12/9/24 9:43:55 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

      SC 13G/A - Oculis Holding AG (0001953530) (Subject)

      11/7/24 4:15:49 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Oculis Holding AG Financials

    Live finance-specific insights

    See more
    • Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

      DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

      5/22/23 6:30:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

      ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

      4/4/23 7:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Oculis Holding AG Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oculis Publishes Invitation to the Annual General Meeting

      ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

      5/9/25 4:05:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Reports Q1 2025 Financial Results and Provides Company Update

      The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor's (OCS-05) positive results from the ACUITY trial in Acute Optic NeuritisOCS-01: DIAMOND Ph3 trials enrollment completed with over 800 patients randomized; topline results expected Q2 2026 for the first potential eye drop treatment for diabetic macular edema (DME)Licaminlimab (OCS-02) genotype-based development plan to drive a personalized medicine approach in dry eye disease (DED) aligned with FDA; first registrational trial initiation anticipated in 2H 2025Cas

      5/8/25 4:05:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Present at Upcoming May Investor Conferences

      ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences: Bio€quity EuropeMay 12-14, 2025; Bruges, BelgiumCompany update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET Bank of America Healthcare ConferenceMay 13-15, 2025; Las Vegas, USAFireside chat with Sylvia Cheung, Chief Financial Officer, on May 14 at 3pm PT H.C. Wainwright Annual BioConnect at NasdaqMay 20, 2025; New York,

      5/7/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

      ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Study interim results will highlight key areas of consensus on unmet needs in DME patient management among leading global experts. Further insights from Stage 1 of the Phase 3 DIAMOND progr

      5/1/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

      ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, will host an in-person and virtual R&D Day today, Tuesday, April 15, 2025 from 10:00 AM to 12:00 PM ET at the Intercontinental New York Barclay hotel. To attend the event or participate virtually, please register here. The event will provide an update on Oculis' portfolio of three innovative late-stage clinical candidates, offer further details on the recently disclosed ACUITY clinical results and outline the anticipated nex

      4/15/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

      DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading record speed across 119 sites worldwide primarily in the US; topline data readout expected in Q2 2026 with NDA submission to followCompany to provide an update on the DIAMOND program and its innovative late-stage pipeline at the upcoming in-person and virtual R&D Day on Tuesday, April 15 ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophth

      4/10/25 8:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

      ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. To register for the event, click here. The event will provide an update on Oculis' portfolio of innovative late-stage clinical candidates, highlight recent clinical data and next steps, as well as discuss future development programs and business strategy. It will

      4/1/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

      Successful 2024 marked by significant clinical advancements across Oculis' late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic (Privosegtor, OCS-05, in acute optic neuritis) and precision medicine (Licaminlimab, OCS-02, in dry eye disease) treatmentsRecent positive topline results in the ACUITY Phase 2 trial showed Privosegtor (OCS-05)'s neuroprotective benefits in anatomical preservation of the retina and visual function improvements in acute optic neuritisOversubscribed $100 million equity financing completed to support the advancement of Oculis' late-stage clinical portfolioUpcoming R&D Day planned on April 15, 2025,

      3/11/25 4:30:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Present at Upcoming March Investor Conference

      ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending and presenting at the following upcoming investor conference: Leerink Global Healthcare ConferencePresenter: Sylvia Cheung, Chief Financial OfficerPresentation date and time: March 11, 2025 at 3:00pm ETLocation: Miami Beach, FL The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institution to request meetings. A live webcast of the fireside c

      3/5/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

      ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the "Offering"). The oversubscribed Offering is expected to close on or about February 18, 2025, subject to satisfaction of customary closing con

      2/13/25 7:39:21 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Oculis Holding AG SEC Filings

    See more
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      5/9/25 4:10:10 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      5/8/25 4:15:13 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      4/15/25 4:05:24 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Oculis Holding AG

      20-F - Oculis Holding AG (0001953530) (Filer)

      3/11/25 4:35:27 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      3/11/25 4:30:05 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      2/14/25 4:28:47 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Oculis Holding AG

      424B5 - Oculis Holding AG (0001953530) (Filer)

      2/14/25 4:03:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oculis Holding AG

      SCHEDULE 13G/A - Oculis Holding AG (0001953530) (Subject)

      2/12/25 4:30:03 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oculis Holding AG

      SCHEDULE 13G/A - Oculis Holding AG (0001953530) (Subject)

      2/11/25 6:52:18 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      1/6/25 4:05:09 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Oculis Holding AG Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

      Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

      12/5/23 8:03:01 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Oculis Holding AG with a new price target

      Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

      10/5/23 7:50:21 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Oculis Holding AG with a new price target

      BofA Securities initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $22.00

      6/14/23 8:10:40 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Oculis Holding AG with a new price target

      H.C. Wainwright initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $28.00

      6/12/23 8:32:05 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Oculis Holding AG with a new price target

      Robert W. Baird initiated coverage of Oculis Holding AG with a rating of Outperform and set a new price target of $58.00

      6/8/23 7:43:11 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pareto initiated coverage on Oculis Holding AG with a new price target

      Pareto initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $23.00

      5/10/23 6:27:47 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Oculis Holding AG with a new price target

      Wedbush initiated coverage of Oculis Holding AG with a rating of Outperform and set a new price target of $27.00

      4/28/23 7:22:50 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Oculis Holding AG Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Invitation to the Annual General Meeting

      ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The 2025 Annual General Meeting will be held in-person and broadcast. To join the broadcast, please use the following link. Information pertaining to the 2025 Annual General Meeting, including meeting materials, can be accessed on the Oculis website here. Oculis will host a virtual information session for all shareholders on May 19, 2025 from 4:00 to 5:00 p.m. CEST / 10:00 to 11:00 a.m. EDT, during

      5/9/25 4:05:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

      Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis' legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leade

      10/2/24 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

      Dr. Klier brings significant experience in ophthalmology and drug development with a proven track record in U.S. FDA approvals, which will be instrumental as the company advances its late-stage pipelineAppointment further expands Oculis' executive leadership team and bolsters U.S. presence ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Dr. Sharon Klier, an executive leader with extensive experience in clinical development across early and late-stage programs, regulatory submissions, and approvals, to the role of Chie

      8/15/24 8:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

      Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & DevelopmentDr. Shah's joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals, which will be key as Oculis initiates preparations for global marketing applications including its first NDA submission to the U.S. FDA ZUG, Switzerland and BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a

      4/10/24 6:30:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

      Completed enrollment in Phase 2b RELIEF trial of Licaminlimab (OCS-02), anti-TNF (tumor necrosis factor) alpha eye drops in Dry Eye Disease (DED); topline results expected in Q2 2024Second Phase 3 trial (DIAMOND-2) of OCS-01 eye drops in Diabetic Macular Edema (DME) initiated as planned, in addition to the ongoing DIAMOND-1 Phase 3 trial initiated in late 2023World-renowned retina specialists, Professor Ramin Tadayoni, M.D., Ph.D. appointed as Chief Scientific Officer and Arshad M. Khanani, M.D., M.A., FASRS appointed as Chair of Oculis' Retina Scientific Advisory Board (SAB)Seasoned HR executive, Virginia R. Dean, appointed as Chief Human Resources Officer in Boston ZUG, Switzerland, a

      2/28/24 6:30:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Reports Q3 2023 Financial Results and Provides Company Update

      Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME)Enrolled first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for treatment of cystoid macular edema (CME)Cash and investments of $116.5 million adequately funded to deliver on key business and clinical milestones ZUG, Switzerland and BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve e

      11/15/23 6:30:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

      Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team with the appointment of Rebecca Weil, Ph.D., seasoned global ophthalmology commercial executive, as Chief Commercial OfficerOCS-01's recent positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) and in Phase 3 OPTIMIZE trial for inflammation and pain following cataract surgery propels Oculis into pre-commercial phase in anticipation of the Company's first US commercial launchIf approved, OCS-01 has the potential to become the first topical preservative-free eye

      9/11/23 6:30:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care